Cargando…

End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis

INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microva...

Descripción completa

Detalles Bibliográficos
Autores principales: Titano, Joseph J., Fischman, Aaron M., Cherian, Arnav, Tully, Madeline, Stein, Lance L., Jacobs, Louis, Rubin, Raymond A., Bosley, Michael, Citron, Steve, Joelson, Dean W., Shrestha, Roshan, Arepally, Aravind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394778/
https://www.ncbi.nlm.nih.gov/pubmed/30635728
http://dx.doi.org/10.1007/s00270-018-2150-6
_version_ 1783398967923441664
author Titano, Joseph J.
Fischman, Aaron M.
Cherian, Arnav
Tully, Madeline
Stein, Lance L.
Jacobs, Louis
Rubin, Raymond A.
Bosley, Michael
Citron, Steve
Joelson, Dean W.
Shrestha, Roshan
Arepally, Aravind
author_facet Titano, Joseph J.
Fischman, Aaron M.
Cherian, Arnav
Tully, Madeline
Stein, Lance L.
Jacobs, Louis
Rubin, Raymond A.
Bosley, Michael
Citron, Steve
Joelson, Dean W.
Shrestha, Roshan
Arepally, Aravind
author_sort Titano, Joseph J.
collection PubMed
description INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microvalve infusion catheters offer a means of such improvement. METHODS: All treatment-naive patients with solitary HCC tumors < 6.5 cm who underwent drug-eluting microspheres (DEM) TACE between 04/2015 and 08/2017 were retrospectively reviewed. Eighty-eight included patients underwent DEM-TACE with either standard end-hole catheters (EH) or microvalve infusion catheters (MVI). The EH (n = 70) and MVI (n = 18) cohorts had similar baseline tumor size, laboratory values, and tumor etiologies. RESULTS: Initial objective response rates were significantly higher in MVI vs. EH (100% vs. 76.5%, p = 0.019). There was no difference in adverse events between groups (p = 0.265). MVI patients exhibited lower AST (p = 0.003) and ALT (p = 0.044) at 6 months. Blinded pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in MVI explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). There was significantly higher percentage tumor necrosis in the MVI group (89.0 ± 2.2%) compared with the EH group (56.1 ± 44.5%) (p = 0.006). CONCLUSION: In this retrospective study of a single-center cohort, DEM-TACE procedures with MVI were associated with improved tumor response, increased deposition of microspheres within tumor tissue, and higher percentage tumor necrosis at explant relative to those performed using EH catheters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2150-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6394778
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-63947782019-03-15 End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis Titano, Joseph J. Fischman, Aaron M. Cherian, Arnav Tully, Madeline Stein, Lance L. Jacobs, Louis Rubin, Raymond A. Bosley, Michael Citron, Steve Joelson, Dean W. Shrestha, Roshan Arepally, Aravind Cardiovasc Intervent Radiol Clinical Investigation INTRODUCTION: Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, and microvalve infusion catheters offer a means of such improvement. METHODS: All treatment-naive patients with solitary HCC tumors < 6.5 cm who underwent drug-eluting microspheres (DEM) TACE between 04/2015 and 08/2017 were retrospectively reviewed. Eighty-eight included patients underwent DEM-TACE with either standard end-hole catheters (EH) or microvalve infusion catheters (MVI). The EH (n = 70) and MVI (n = 18) cohorts had similar baseline tumor size, laboratory values, and tumor etiologies. RESULTS: Initial objective response rates were significantly higher in MVI vs. EH (100% vs. 76.5%, p = 0.019). There was no difference in adverse events between groups (p = 0.265). MVI patients exhibited lower AST (p = 0.003) and ALT (p = 0.044) at 6 months. Blinded pathological analysis of explanted livers showed greater concentrations of microspheres within the tumor relative to the surrounding tissue in MVI explants (88.7 ± 10.6%) versus the EH explants (55.3 ± 32.7%) (p = 0.002). There was significantly higher percentage tumor necrosis in the MVI group (89.0 ± 2.2%) compared with the EH group (56.1 ± 44.5%) (p = 0.006). CONCLUSION: In this retrospective study of a single-center cohort, DEM-TACE procedures with MVI were associated with improved tumor response, increased deposition of microspheres within tumor tissue, and higher percentage tumor necrosis at explant relative to those performed using EH catheters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00270-018-2150-6) contains supplementary material, which is available to authorized users. Springer US 2019-01-11 2019 /pmc/articles/PMC6394778/ /pubmed/30635728 http://dx.doi.org/10.1007/s00270-018-2150-6 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Investigation
Titano, Joseph J.
Fischman, Aaron M.
Cherian, Arnav
Tully, Madeline
Stein, Lance L.
Jacobs, Louis
Rubin, Raymond A.
Bosley, Michael
Citron, Steve
Joelson, Dean W.
Shrestha, Roshan
Arepally, Aravind
End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title_full End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title_fullStr End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title_full_unstemmed End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title_short End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
title_sort end-hole versus microvalve infusion catheters in patients undergoing drug-eluting microspheres-tace for solitary hepatocellular carcinoma tumors: a retrospective analysis
topic Clinical Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394778/
https://www.ncbi.nlm.nih.gov/pubmed/30635728
http://dx.doi.org/10.1007/s00270-018-2150-6
work_keys_str_mv AT titanojosephj endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT fischmanaaronm endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT cherianarnav endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT tullymadeline endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT steinlancel endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT jacobslouis endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT rubinraymonda endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT bosleymichael endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT citronsteve endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT joelsondeanw endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT shrestharoshan endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis
AT arepallyaravind endholeversusmicrovalveinfusioncathetersinpatientsundergoingdrugelutingmicrospherestaceforsolitaryhepatocellularcarcinomatumorsaretrospectiveanalysis